{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of September 2023): No"],"condition":["Colorectal Cancer","Colorectal Neoplasms","RAS wild-type colorectal cancer","Cáncer colorrectal RAS nativo"],"disease":["Ras Wild-type Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms","Cáncer Colorrectal Ras Nativo"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/106"],"location":["Belgium","Czechia","Italy","France","Spain"],"study_start_month":["12"],"keyword":["AURELIO-05","SOT101","Cetuximab","Nanrilkefusp alfa","SO-C101"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer","description":"The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.","dates":{"creation":"2022-12-15"},"accession":"106","cross_references":{"ClinicalTrials___gov":["NCT05619172"],"EU Clinical Trials Register":["2022-001527-32"]}}